Liver News and Research

RSS

Depression can sabotage efforts to effectively treat Hepatitis C

Adherence to interferon, an important medication used to treat Hepatitis C, is critical to successfully clearing the virus that causes the disease. A new observational analysis by Medco Health Solutions, Inc. finds that when Hepatitis C patients are also being treated for depression -- a frequent side effect of interferon use -- they are more likely to remain on their interferon therapy.

12 Apr 2011

Study shows neutralizing antibodies to C5a protein may prevent heart failure

New research published online in The FASEB Journal details research in rats and mice that offers hope for stopping the devastating, and often fatal, effects of sepsis in humans. In the study, University of Michigan researchers show how neutralizing the effects of a key protein fragment, called C5a, used by the immune system to attract white blood cells may ultimately prevent heart failure.

12 Apr 2011

Study shows how specific nutritional combination may help maintain healthy breast tissue

Researchers from Canada and the United States today told attendees of the Experimental Biology 2011 Scientific Meeting that they have uncovered a possible means of enabling women to favorably influence whether the estrogens in their bodies take a "beneficial path" or a "disease-potential" path.

11 Apr 2011

Key regulator of fat cell development may provide a target for obesity and diabetes drugs

New research by scientists at The Scripps Research Institute and collaborating institutions has identified a key regulator of fat cell development that may provide a target for obesity and diabetes drugs.

8 Apr 2011

New report finds 13,000 cancer cases per year in the UK due to alcohol consumption

Alcohol causes at least 13,000 cases of cancer a year in the UK, according to a new report published in the British Medical Journal today.

8 Apr 2011

Experimental Biology 2011 to be held April 9-13 in Washington, D.C.

The meeting Experimental Biology 2011 (EB 2011) begins April 9 and runs through April 13 at the Walter E. Washington Convention Center in Washington, D.C.

8 Apr 2011

New publication on therapeutic hypothermia and temperature management

The successful use and evaluation of therapeutic hypothermia to improve survival and reduce the risk of neurological consequences following an out-of-hospital heart attack are explored in the premier issue of Therapeutic Hypothermia and Temperature Management, a new quarterly peer-reviewed journal published by Mary Ann Liebert, Inc.

8 Apr 2011

HALT-C trial reveals high mortality rates among patients with HCV

A three-year follow-up study of patients in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial revealed that increased mortality among patients with advanced chronic hepatitis C who received long-term peginterferon therapy was attributed to non-liver related causes and occurred primarily in patients with bridging fibrosis.

8 Apr 2011

Increased mortality rates seen in chronic Hep C patients with pre-cirrhotic advanced fibrosis

A three-year follow-up study of patients in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial revealed that increased mortality among patients with advanced chronic hepatitis C who received long-term peginterferon therapy was attributed to non-liver related causes and occurred primarily in patients with bridging fibrosis. No pattern to this excess mortality was evident to researchers, but deaths were unrelated to the peginterferon treatment. Full findings are published in the April issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases (AASLD).

7 Apr 2011

Alcohol raises risk of cancers: Study

This comes from a large Europe-wide study published in the British Medical Journal that found that one-in-10 of all cancers in men and one-in-33 of all cancers in women are caused by past or current alcohol intake. For alcohol-related cancers, one-in-three in men and one-in-20 in women are caused by any excessive drinking. According to cancer charities say people should limit their drinking to lower the risk.

7 Apr 2011

Alnylam to extend RNAi therapeutics research collaboration with AlCana and UBC

AlCana Technologies, Inc., The University of British Columbia, and Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that Alnylam has elected to extend the companies' RNAi therapeutics research collaboration for a third year.

7 Apr 2011

TBL1 levels may help identify obese persons at risk of developing fatty liver

Excess fat around the hips and belly may not really be compatible with current beauty ideals, but, to a certain degree, it is a normal, even vital energy store of our body. However, it is a different matter if the organism stores fat in organs such as the liver, pancreas or muscles. This is a clear sign of a metabolic disorder.

7 Apr 2011

Novel strategy to build molecular probes may lead to development of new cancer drugs

Chemical engineers at UC Santa Barbara expect that their new process to create molecular probes may eventually result in the development of new drugs to treat cancer and other illnesses.

7 Apr 2011

Navigator-3 gene plays a key role in liver development

Scientists of the Max Delbr-ck Center for Molecular Medicine Berlin-Buch have demonstrated for the first time that a gene regulating neuronal cell migration during embryogenesis also plays a role in the development of the liver.

7 Apr 2011

Supplements are less well regulated than drugs and may have side effects, drug interactions and toxicities

Vitamins, herbs and other dietary supplements are sold as natural alternatives to pharmaceuticals and many people turn to them in an attempt to improve their health. Others seek supplements to lose weight or after hearing that they can help with serious medical conditions.

7 Apr 2011

NIH awards HemoShear with Phase I SBIR grant to develop rodent liver system

HemoShear, LLC, is pleased to announce that it was awarded a Phase 1 Small Business Innovation Research grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health.

7 Apr 2011

Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

Takeda Pharmaceuticals North America, Inc. announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate). The results showed that in healthy subjects, clopidogrel's active metabolite and inhibition of platelet function were reduced less by the co-administration of clopidogrel with dexlansoprazole or lansoprazole, rather than esomeprazole.

6 Apr 2011

AMPK suppression and SREBP activation are root cause of fatty liver and hyperlipidemia in type 2 diabetes

Researchers from Boston University School of Medicine, including Yu Li, PhD, and other colleagues, have demonstrated that a nutrient sensing pathway is involved in the disruption of cellular lipid homeostasis in obese and insulin resistant mice fed a diet high in fat and sucrose.

6 Apr 2011

J&JPRD announces rivaroxaban Phase 3 trial results against venous thromboembolism

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., today announced results from the MAGELLAN Phase 3 trial evaluating the investigational oral anticoagulant rivaroxaban for the prevention of venous thromboembolism in hospitalized patients with acute medical illnesses.

6 Apr 2011

Scientists uncover SREBP-2 role in autophagy and cholesterol generation

Not all cholesterol is bad. Every cell requires it for growth - they either have to get cholesterol somewhere or they die. In a new study published April 6 in the journal Cell Metabolism, researchers from Sanford-Burnham Medical Research Institute and their collaborators found that a protein sensor known to balance cholesterol sources can also access a previously underappreciated cellular fat storage depot.

6 Apr 2011

Liver News and Research

Depression can sabotage efforts to effectively treat Hepatitis C

Study shows neutralizing antibodies to C5a protein may prevent heart failure

Study shows how specific nutritional combination may help maintain healthy breast tissue

Key regulator of fat cell development may provide a target for obesity and diabetes drugs

New report finds 13,000 cancer cases per year in the UK due to alcohol consumption

Experimental Biology 2011 to be held April 9-13 in Washington, D.C.

New publication on therapeutic hypothermia and temperature management

HALT-C trial reveals high mortality rates among patients with HCV

Increased mortality rates seen in chronic Hep C patients with pre-cirrhotic advanced fibrosis

Alcohol raises risk of cancers: Study

Alnylam to extend RNAi therapeutics research collaboration with AlCana and UBC

TBL1 levels may help identify obese persons at risk of developing fatty liver

Novel strategy to build molecular probes may lead to development of new cancer drugs

Navigator-3 gene plays a key role in liver development

Supplements are less well regulated than drugs and may have side effects, drug interactions and toxicities

NIH awards HemoShear with Phase I SBIR grant to develop rodent liver system

Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

AMPK suppression and SREBP activation are root cause of fatty liver and hyperlipidemia in type 2 diabetes

J&JPRD announces rivaroxaban Phase 3 trial results against venous thromboembolism

Scientists uncover SREBP-2 role in autophagy and cholesterol generation

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News